Honeysuckle Magazine, December 29, 2021: There has been a 33 percent increase in cosmetic surgery for women between 2000 and 2020. However, the measures meant to guarantee their safety are disputed among experts such as the National Center for Health Research.
Read More »We’re In The News
As a respected nonprofit health research center, our views are often quoted in the media, including newspapers, magazines, TV, radio, and websites. We also write articles and blogs for a number of different and highly respected newspapers, magazines, and popular websites, and we are published in prestigious medical journals and health policy publications. We frequently express our policy views in letters to government officials and public comments to federal agencies and we sometimes release statements or press releases on newsworthy issues.
Please e-mail info@center4research.org or call 202-223-4000 with your inquiries. We can assist you with scheduling interviews with the NCHR President, Dr. Diana Zuckerman, and other experts on our staff.
Pfizer Covid Pill’s Fast Signoff Spurs Row Over Skipped Step
Bloomberg Law, December 22, 2021: The FDA authorized Pfizer Inc.’s pill to treat Covid-19 without first getting input from an expert advisory panel. We explain why that could further undermine trust in an agency already facing scrutiny over its rapid decision-making during the pandemic.
Read More »Califf heads to Capitol Hill for FDA confirmation hearing
Politico, December 14, 2021: FDA Commissioner nominee Dr. Robert Califf makes his case for the job before the Senate health panel. We ask: What will he do about accelerated approval of ineffective medical treatments?
Read More »Equal Access to Merck Covid Pill Imperiled by Prescribing Rules
Bloomberg Law, December 2, 2021: Merck’s antiviral drug molnupiravir—if authorized by the agency—would offer for the first time in the U.S. an at-home treatment option for patients with mild to moderate Covid-19 who are at risk of severe disease.
Read More »Biden’s Drug Agency Nominee Returns With Deeper Industry Ties
Bloomberg Business, November 23, 2021: President Biden’s choice to lead the FDA made millions of dollars from health and drug companies since his last stint in government, raising new questions about his ties to firms the agency oversees.
Read More »